Deciphera Pharmaceuticals LLC (DCPH) Peer Comparison

$25.61

$0.04 (0.16%)

As on 10-Jun-2024 16:09EDT

Market cap

$2,213 Mln

Revenue (TTM)

$175 Mln

P/E Ratio

--

P/B Ratio

7

Div. Yield

0 %

Edit

	Deciphera Pharmaceuticals LLC (DCPH)	Landos Biopharma (LABP)	First Wave BioPharma (FWBI)
Market cap ($ Mln)	2,213	72	6
Revenue ($ Mln)	175	--	0
Net Profit ($ Mln)	-190.42	-24.80	-6.16
Net Margin (%)	-106.30	--	-4,436.70
RoE (%)	-54.58	-81.55	-15.18
Price to Earnings	--	--	--
Price-To-Book	7.00	2.11	1.87

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Deciphera Pharmaceuticals LLC (DCPH)	Landos Biopharma (LABP)	First Wave BioPharma (FWBI)
Operating Revenue	174.91	0.00	0.14
Cost of Revenue	6.93	0.00	0.07
Gross Profit	159.62	--	-0.03
Operating Expenses	374.53	25.24	20.91
Operating Profit (EBIT)	-206.55	-25.24	-20.93
Other Income	4.21	0.00	0.00
Profit before Tax	-189.99	-24.80	-21.02
Provision for Tax	-0.03	0.45	-14.86
Profit after Tax (Net Income)	-190.42	-24.80	-6.16
Minority Interest	0.00	0.00	0.00
Consolidated Profit	-48.56	-3.92	0.00

Liabilities ($ Mln)

	Deciphera Pharmaceuticals LLC (DCPH)	Landos Biopharma (LABP)	First Wave BioPharma (FWBI)
Shareholder's Funds	316.05	23.15	77.86
Minority Interest	0.00	0.00	0.00
Non-Current Liabilities	21.45	0.00	7.10
Current Liabilities	83.43	6.74	6.17
Total Liabilities	473.57	38.04	6.88

Assets ($ Mln)

	Deciphera Pharmaceuticals LLC (DCPH)	Landos Biopharma (LABP)	First Wave BioPharma (FWBI)
Non-Current Assets	70.99	0.00	83.64
Current Assets	349.94	29.90	7.49
Total Assets	473.57	38.04	6.88
Total Debt*	25.02	0.00	6.98
Net Current Assets	266.51	23.15	1.32

Cashflow ($ Mln)

	Deciphera Pharmaceuticals LLC (DCPH)	Landos Biopharma (LABP)	First Wave BioPharma (FWBI)
Cash From Operating Activities	-146.70	-20.48	-12.38
Cash Flow from Investing Activities	--	--	--
Cash from Financing Activities	152.00	13.57	15.23
Net Cash Inflow / Outflow	--	--	--

Ratios

Profitability Ratios

	Deciphera Pharmaceuticals LLC (DCPH)	Landos Biopharma (LABP)	First Wave BioPharma (FWBI)
ROCE (%)	-52.15	-61.86	-392.15
ROE (%)	-54.58	-81.55	-15.18
ROA (%)	-33.49	-53.92	-11.68
EBIT Margin (%)	-118.35	--	-15,087.22
Net Margin (%)	-106.30	--	-4,436.70
Cash Profit Margin (%)	0.00	--	-0.13

Growth Ratios

	Deciphera Pharmaceuticals LLC (DCPH)	Landos Biopharma (LABP)	First Wave BioPharma (FWBI)
Revenue Growth (%)	26.51	--	--
EBIT Growth (%)	-8.78	66.02	-184.52
Net Profit Growth (%)	-7.87	13.70	42.99
EPS Growth (%)	2.78	39.58	--
Book Value Growth (%)	-31.49	-48.57	--

Valuation Ratios

	Deciphera Pharmaceuticals LLC (DCPH)	Landos Biopharma (LABP)	First Wave BioPharma (FWBI)
Price / Earnings	-7.03	-1.04	--
Price / Book Value	3.91	0.71	--
Dividend Yield (%)	--	--	--
EV/EBITDA	-5.17	0.65	0.18
Market Cap ($ Cr)	--	--	--

Solvency Ratios

	Deciphera Pharmaceuticals LLC (DCPH)	Landos Biopharma (LABP)	First Wave BioPharma (FWBI)
Debt to Equity	0.00	0.00	0.08
Short term debt to equity ratio	0.01	0.00	0.01
Current Ratio	4.19	4.43	1.21
Quick Ratio	3.94	4.43	1.21
Interest Coverage	-51.08	-13.08	-262.77

Operating Efficiency Ratios

	Deciphera Pharmaceuticals LLC (DCPH)	Landos Biopharma (LABP)	First Wave BioPharma (FWBI)
Debtors to sales (%)	18.69	--	0.00
Asset Turnover	0.31	0.00	0.00
Receivable days	60.80	--	--
Inventory Days	2,044.06	--	--
Payable days	2,206.38	--	7,949.79
Cash Conversion Cycle	-101.52	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly